SR8278

SR8278 is a synthetic compound that has been identified as a ligand for the Rev-ErbA alpha and Rev-ErbA beta receptors. These receptors are members of the nuclear receptor family of intracellular transcription factors and play a crucial role in regulating the circadian rhythm and metabolism in mammals.

Chemistry

SR8278 is a small molecule that was designed to bind to the ligand-binding domain of the Rev-Erb receptors. It is a hydrophobic compound with a molecular weight of approximately 500 Daltons. The exact chemical structure of SR8278 is proprietary information and is not publicly available.

Mechanism of Action

SR8278 acts as an antagonist for the Rev-Erb receptors. It binds to the ligand-binding domain of these receptors and inhibits their activity. This results in the disruption of the normal circadian rhythm and metabolic processes regulated by these receptors.

Pharmacology

The pharmacokinetics of SR8278 have not been extensively studied. However, it is known that the compound is orally bioavailable and can cross the blood-brain barrier. The exact half-life, clearance rate, and volume of distribution of SR8278 in humans are currently unknown.

Clinical Applications

SR8278 has been studied for its potential use in the treatment of various diseases, including sleep disorders, metabolic disorders, and cancer. However, these studies are still in the early stages and the safety and efficacy of SR8278 in humans have not been established.

Research

Research on SR8278 is ongoing, with studies focusing on its potential use in the treatment of sleep disorders, metabolic disorders, and cancer. These studies are still in the early stages and more research is needed to fully understand the potential benefits and risks of SR8278.

See Also

• Rev-ErbA alpha
• Rev-ErbA beta
• Nuclear receptor
• Circadian rhythm
• Metabolism

References

‎